Shares of Insmed, Inc. (NASDAQ:INSM – Get Free Report) passed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $112.33 and traded as low as $109.22. Insmed shares last traded at $109.31, with a volume of 4,240,345 shares trading hands.
Analyst Upgrades and Downgrades
INSM has been the subject of several analyst reports. Stifel Nicolaus set a $195.00 price objective on shares of Insmed in a research note on Thursday. BMO Capital Markets restated an “outperform” rating on shares of Insmed in a research report on Tuesday, October 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a report on Thursday, October 15th. JPMorgan Chase & Co. dropped their price target on shares of Insmed from $179.00 to $175.00 and set an “overweight” rating for the company in a research report on Monday, August 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $235.00 price target on shares of Insmed in a research note on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $196.52.
Get Our Latest Stock Analysis on INSM
Insmed Stock Down 2.9%
The company has a market cap of $23.87 billion, a P/E ratio of -38.76 and a beta of 0.83. The stock has a 50-day moving average of $112.33 and a 200 day moving average of $125.41. The company has a debt-to-equity ratio of 0.74, a current ratio of 3.72 and a quick ratio of 3.40.
Insmed (NASDAQ:INSM – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The firm had revenue of $524.43 million for the quarter, compared to the consensus estimate of $500.36 million. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%. The company’s revenue for the quarter was up 268.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.75) EPS. Research analysts anticipate that Insmed, Inc. will post -1.62 earnings per share for the current year.
Insider Activity at Insmed
In other news, Director David Brennan sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total value of $3,100,000.00. Following the completion of the transaction, the director directly owned 39,238 shares in the company, valued at approximately $4,865,512. The trade was a 38.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Roger Adsett sold 239,850 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the sale, the chief operating officer directly owned 98,744 shares of the company’s stock, valued at approximately $13,159,612.88. This trade represents a 70.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.10% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the company. CenterBook Partners LP boosted its holdings in shares of Insmed by 10.2% in the 3rd quarter. CenterBook Partners LP now owns 113,720 shares of the biopharmaceutical company’s stock valued at $12,980,000 after purchasing an additional 10,569 shares in the last quarter. Heritage Family Offices LLP acquired a new position in shares of Insmed during the 3rd quarter worth $60,000. Waldron Private Wealth LLC raised its holdings in shares of Insmed by 1.1% during the 3rd quarter. Waldron Private Wealth LLC now owns 8,910 shares of the biopharmaceutical company’s stock worth $1,017,000 after buying an additional 100 shares in the last quarter. Calamos Advisors LLC raised its holdings in shares of Insmed by 251.0% during the 3rd quarter. Calamos Advisors LLC now owns 29,859 shares of the biopharmaceutical company’s stock worth $3,408,000 after buying an additional 21,352 shares in the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in shares of Insmed during the 3rd quarter worth $485,000.
Insmed Company Profile
Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.
Insmed’s lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.
Featured Stories
- Five stocks we like better than Insmed
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
